Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study

por Gambacorti‐Passerini, Carlo, Orlov, Sergey, Zhang, Li, Braiteh, Fadi, Huang, Huiqiang, Esaki, Taito, Horibe, Keizo, Ahn, Jin‐Seok, Beck, Joseph T., Edenfield, William Jeffrey, Shi, Yuankai, Taylor, Matthew, Tamura, Kenji, Van Tine, Brian A., Wu, Shang‐Ju, Paolini, Jolanda, Selaru, Paulina, Kim, Tae Min
Publicado 2018